Abstract: Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described.

Abstract: A system for applying a protective overlay on construction tracks being carried along a work path is provided. The system includes an adhesive dispensing unit provided along the work path and has a dispenser operable to dispense adhesive to a surface of the construction tracks. The system also includes an overlay feeding unit operatively mounted about the work path and which has one or more feeder rolls adapted to guide and feed a length of protective overlay from a supply of protective overlay along a feeding course above the work path. The system further includes an affixing unit provided along the work path following the feeding course. The affixing unit includes an applicator adapted to generate an affixing force to secure the length of protective overlay from the feeding course on the construction tracks.

Abstract: Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described.

Abstract: Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described.

Abstract: Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described.

Abstract: The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resulting antibodies. Improved methods of more directly and precisely conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including “click-chemistry” approaches based on photocatalytic thiol-ene reactions.

Abstract: The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resulting antibodies. Improved methods of more directly and precisely conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including “click-chemistry” approaches based on photocatalytic thiol-ene reactions.

Abstract: The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resulting antibodies. Improved methods of more directly and precisely conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including “click-chemistry” approaches based on photocatalytic thiol-ene reactions.

Abstract: The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype conjugated to a carrier protein. The immunogenic composition is useful for the protection of disease in an animal subject.

Abstract: A multipoint tie-down formed of EPDM for reducing movement of a load. The tie-down comprises a central hub having a plurality of elongate arms that are molded from EPDM as a single unit with the central hub. The plurality of elongate arms are elastomeric and extend from the central hub to form one of a cross-pattern, a Y-pattern and an X-pattern together with the central hub.

Abstract: A multipoint tie-down formed of EPDM for reducing movement of a load. The tie-down comprises a central hub having a plurality of elongate arms that are molded from EPDM as a single unit with the central hub. The plurality of elongate arms are elastomeric and extend from the central hub to form one of a cross-pattern, a Y-pattern and an X-pattern together with the central hub.

Abstract: A piezo-electric sound pickup device for a stringed instrument having a wood or other shapeable material for a casing that is slightly larger than the standard gap between the wing and leg of the instrument bridge. The sound pickup device can be sanded to the proper dimension to properly fit this wing to leg gap. The installation of the pickup after proper sizing does not change the tone of the instrument and does not require further shim installation.

Abstract: The present invention relates to the field of the Medicine, in particular with the chemical synthesis of oligosaccharide mixtures derived of ribose-ribitol-phosphate, which are used as active principle in vaccines for the prevention of infections caused by Haemophilus influenzae type b (Hib), as well as with the vaccines containing said oligosaccharide mixtures. The oligasaccharide mixtures obtained by chemical synthesis of the present invention, comprise repeating units of formulae (phosphate-ribosa-ribitol)n or (ribose-ribitol-phosphate)n of at least 5 compounds of structure A or B, which represent the repeating unit of the capsular polysaccharide of Haemophilus influenzae type b and differ only by n, being n a value contained between 4 and 25 (n≧4 y≦25), and wherein R1 or R2 is a spacer for conjugation to a carrier, with the condition of R1=spacer if R2=H, or R2=spacer if R1=H.

Abstract: A radioactive implant characterized by a biological effectiveness comparable to that of palladium-103 and, simultaneously, by a half-life of the order of that of iodine-125. More specifically, the present invention provides a radioactive implant having improved biological effectiveness, by lowering the average energy of the photon spectrum of a relatively long half-life radioisotope element using x-ray fluorescence. Selection of a fluorescent material within elements having an atomic number between 39 and 45, preferably between 40 and 42, for surrounding a radioactive inner core comprising the radioisotope element, is described.

Abstract: A compound X-Y wherein X comprises sialic acid, a sialic acid derivative or and oligosaccharide terminating in a sialic acid or sialic acid derivative if multibranched at the end of at least the largest branch, and, Y represents coupling means which allows an antibody to be raised to X when the compound is coupled to a carrier through the coupling nears Y and the coupled compound used to raise said antibody. These compounds show utility in that they, and antibodies raised against these, can be used in detecting and diagnosing cancers.

Abstract: A compound X-Y wherein X comprises sialic acid, a sialic acid derivative or an oligosaccharide terminating in a sialic acid or sialic acid derivative if multibranched at the end of at least the largest branch, and, Y represents coupling means which allows an antibody to be raised to X when the compound is coupled to a carrier through the coupling means Y and the coupled compound used to raise said antibody. These compounds show utility in that they, and antibodies raised against these, can be used in detecting and diagnosing cancers.

Abstract: The group B polysaccharide of Neisseria meningitidis is chemically modified to enhance the immune response thereto, thereby providing cross-reactive antibodies of high affinity. The N-acetyl group of the sialic acid residues of the polysaccharide has been substituted by the N-propionyl group, and this modified antigen then conjugated to a physiologically-acceptable protein such as tetanus toxoid. This conjugate vaccine has been found to raise high titers of high affinity group B IgG antibodies and would be useful against meningitis caused by group B N. meningitidis or by E. coli KI organisms.